Tag Archive for: MindMed
MindMed: Can the Former Darlings of the Psychedelic Biotech Sector Avoid Collapse?
BusinessAfter MindMed's up-listing, the company has been facing a lot of instability and turbulence in the past few months and years. It has been struggling to establish stability in a sector that is still struggling.
Phase II Study Shows LSD Is Effective In Treating Major Depressive Disorder
ResearchData from a Phase 2 clinical trial involving LSD-assisted psychotherapy show LSD as effective treatment for Major Depressive Disorder.
Math Over Myth: Weekly Psychedelic Stocks News Roundup
Business, Stock ReportsGet the latest news on psychedelic stocks Cybin, Numinus, MindMed, ATAI, Mindset, Braxia, Tryp, Irwin Naturals, and Revive
Math Over Myth: September Psychedelic Stock News Roundup
Business, Stock ReportsTrack the monthly performance of the psychedelic stock sector with our Math over Myth Stock News Roundup
Math Over Myth: MindMed’s Self Destructive Stock Mission
Business, Stock ReportsPsychedelic stock MindMed enters free fall as news of a private equity offering of common stock spooks retail investors
Math Over Myth: Spotlight on MindMed
Business, Stock ReportsIn the latest installment of Math Over Myth we navigate psychedelic stock MindMed’s reverse split with Fibonacci numbers
Psychedelic Stocks: MindMed and atai Slash their Pipelines, Mydecine Collapses
Business, Stock ReportsThe psychedelic renaissance hits a rough patch as major companies look to tighten their belts or face total collapse. What’s happening with Psychedelic Stocks?
MindMed Shelves 18-MC for Opioid Use Disorder and Further Cuts Pipeline
Business, Stock ReportsMindMed drops its proprietary ibogaine for opioid addiction research amidst an ongoing shakeup. What is going on with this psychedelics company?
3 Microdosing Clinical Trials to Keep an Eye On
Business, ResearchDoes microdosing psychedelics work, or is it the placebo effect? Here are 3 microdosing clinical trials looking for answers
The Battle for Psychedelic Patents
Business, NewsPsychedelic companies rely on novel patents to boost their value, but many players in the space are chasing the same IP